ArticleExperimental and therapeutic medicine2018
Plasma miR-136 can be used to screen patients with knee osteoarthritis from healthy controls by targeting IL-17.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- MicroRNAs in the diagnosis of osteoarthritis: a systematic review and meta-analysis of observational studies.Journal of orthopaedic surgery and research · 2025Pooled it
- Association between the polymorphism of IL-17A and IL-17F gene with knee osteoarthritis risk: a meta-analysis based on case-control studies.Journal of orthopaedic surgery and research · 2019Pooled it
- Osteoarthritis: Epidemiology, Diagnosis, and Treatment.MedComm · 2026Review
- Revealing the regulatory role of lncRNAs SNHG1 and CRNDE on Th17/Treg imbalance in diabetic kidney disease.Clinical and experimental medicine · 2025Article
- Exploring the Feasibility of Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Osteoarthritis: Challenges and Opportunities.International journal of molecular sciences · 2023Review
- IL-17 in osteoarthritis: A narrative review.Open life sciences · 2023Review
- Circulating and extracellular vesicle-derived microRNAs as biomarkers in bone-related diseases.Frontiers in endocrinology · 2023Review
- Cytokines and microRNAs in SARS-CoV-2: What do we know?Molecular therapy. Nucleic acids · 2022Review
- Serum and Synovial Fluid Levels of Interleukin-17A in Primary Knee Osteoarthritis Patients: Correlations With Functional Status, Pain, and Disease Severity.Archives of rheumatology · 2022Article
- Mesenchymal stem cell-derived exosomal microRNA-136-5p inhibits chondrocyte degeneration in traumatic osteoarthritis by targeting ELF3.Arthritis research & therapy · 2020Article
- The Clinical Potential of Circulating miRNAs as Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated Bone Diseases.Biomolecules · 2020Review
- Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update.Clinical interventions in aging · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study mainly evaluated the plasma level of microRNA (miR)-136 in knee osteoarthritis (KOA) patients and determined if miR-136 could be used as a potential biomarker to screen KOA patients from healthy controls. It was demonstrated that plasma miR-136 was significantly decreased in the plasma of KOA patients. Moreover, the reduction in plasma miR-136 negatively correlated with the severity of KOA. Additionally, the increase in the serum interleukin (IL)-17 level positively correlated with the severity of KOA. More importantly, dual luciferase assays and western blot assays indicated that IL-17 was a target gene of miR-136. Further analysis showed that plasma miR-136 could be used as a biomarker to screen KOA patients from healthy controls. In summary, for the first time, the present study revealed that through targeting IL-17, decreased plasma miR-136 levels could be used as a potential biomarker to screen KOA patients from healthy controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.